Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review

International Journal of Clinical Pharmacy

Volumn 36, Issue 6, 2014, Pages 1115-1125

  Alsalimy, Noor ^a   Awaisu, Ahmed ^b  

^a HAMAD MEDICAL CORPORATION   (Qatar)

^b Qatar University ^*  (Qatar)

Author keywords

Anemia; CERA; Chronic kidney disease; EPO; Erythropoiesis stimulating agent; Methoxy polyethylene glycol epoetin beta; Pre dialysis; Review

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ANTIANEMIC AGENT; ERYTHROPOIETIN; MACROGOL DERIVATIVE;

ANEMIA; ANGIONEUROTIC EDEMA; CHRONIC KIDNEY DISEASE; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPERKALEMIA; HYPERTENSION; MACULOPAPULAR RASH; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SHORT FORM 36; SOCIAL INTERACTION; SYSTEMATIC REVIEW; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY;

ANEMIA; CLINICAL TRIALS AS TOPIC; ERYTHROPOIETIN; HEMATINICS; HUMANS; POLYETHYLENE GLYCOLS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84921936435     PISSN: 22107703     EISSN: 22107711     Source Type: Journal    
DOI: 10.1007/s11096-014-0023-x     Document Type: Review

References (56)

1. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med. 2002;162:1401–8.
2. McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20:1501–10.
3. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. AJKD. 2012;60:850–86.
4. McCarley P. The KDOQI clinical practice guidelines and clinical practice recommendations for treating anemia in patients with chronic kidney disease: implications for nurses. Nephrol Nurs J. 2006;33:423–6.
5. Silverberg DS, Wexler D, Iaina A, Steinbruch S, Wollman Y, Schwartz D. Anemia, chronic renal disease and congestive heart failure—the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int J Nephrol Urol. 2006;38:295–310.
6. Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, et al. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Clin Ther. 2007;29:626–39.
7. Ershler WB, Chen K, Reyes EB, Dubois R. Economic burden of patients with anemia in selected diseases. Value Heal. 2005;8:629–38.
8. Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Hear J. 2006;151:492–500.
9. US rHuEPO Predialysis Study Group. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients The US Recombinant Human Erythropoietin Predialysis Study Group. AJKD. 1991;18:50–9.
10. Locatelli F, Del Vecchio L. Erythropoiesis-stimulating agents in renal medicine. Oncologist. 2011;16(Suppl 3):19–24.
11. Macdougall IC. Novel erythropoiesis-stimulating agents: a new era in anemia management. CJASN. 2008;3:200–7.
12. Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther. 1991;50:702–12.
13. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. JASN. 1999;10:2392–5.
14. Macdougall IC. Optimizing the use of erythropoietic agents—pharmacokinetic and pharmacodynamic considerations. Neph Dial Trans. 2002;17(Suppl 5):66–70.
15. Robinson DM, Easthope SE. Darbepoetin alfa: its use in anemia associated with chronic kidney disease. BioDrugs. 2005;19:327–43.
16. Ohashi N, Sakao Y, Yasuda H, Kato A, Fujigaki Y. Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease. Int J Nephrol Renov Dis. 2012;5:53–60.
17. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt K-U, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Neph Dial Trans. 2004;19(Suppl 2):ii1–47.
18. Carrera F, Disney A, Molina M. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data. Neph Dial Trans. 2007;22(Suppl 4):iv19–30.
19. Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet. 1991;20:99–113.
20. Macdougall IC, Padhi D, Jang G. Pharmacology of darbepoetin alfa. Neph Dial Trans. 2007;22(Suppl 4):iv2–9.
21. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (CERA) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:1211–5.
22. Topf JM. CERA: third-generation erythropoiesis-stimulating agent. Expert Opin Pharmacother. 2008;9:839–49.
23. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A) in patients with chronic kidney disease. CJASN. 2006;1:1211–5.
24. Roche. Mircera (methoxy polyethylene glycol-epoetin beta)—Product Information 2011.
25. Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Neph. 2007;67:306–17.
26. Levin NW, Fishbane S, Cañedo FV, Zeig S, Nassar GM, Moran JE, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet. 2007;370:1415–21.
27. Sulowicz W, Locatelli F, Ryckelynck J-P, Balla J, Csiky B, Harris K, et al. Once-monthly subcutaneous CERA maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. CJASN. 2007;2:637–46.
28. Drüeke TB, Locatelli F, Clyne N, Eckardt K-U, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. NEJM. 2006;355:2071–84.
29. Panchapakesan U, Sumual S, Pollock C. Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator). Int J Nanomedicine. 2007;2:33–8.
30. Taéron C. Methoxy polyethylene glycol epoetin beta. Rev Infirm. 2010;159:47–9.
31. Schmidt RJ. Methoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off? Expert Opin Pharmacother. 2009;10:1509–14.
32. Curran MP, McCormack PL. Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs. 2008;68:1139–56.
33. Macdougall IC. New anemia therapies: translating novel strategies from bench to bedside. AJKD. 2012;59:444–51.
34. Fink J, Blahut S, Reddy M, Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. AJKD. 2001;37:348–55.
35. Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Neph Dial Trans. 2003;18(Suppl 2):ii2–6.
36. Gouva C, Nikolopoulos P, Ioannidis JPA, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kid Inter. 2004;66:753–60.
37. Aizawa K, Takeda S, Tashiro Y, Yorozu K, Hirata M, Kanada H, et al. Renoprotection by continuous erythropoietin receptor activator in puromycin aminonucleoside-induced nephrotic syndrome. Am J Nephrol. 2012;36:419–26.
38. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. NEJM. 2006;355:2085–98.
39. Pfeffer MA, Burdmann EA, Chen C-Y, Cooper ME, de Zeeuw D, Eckardt K-U, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. NEJM. 2009;361:2019–32.
40. Higgins JPT, Green S. Guide to the contents of a cochrane protocol and review. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The cochrane collaboration, 2011. www.cochrane-handbook.org.
41. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Con Clin Trials. 1996;17:1–12.
42. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
43. Roger SD, Locatelli F, Woitas RP, Laville M, Tobe SW, Provenzano R, et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Neph Dial Trans. 2011;26:3980–6.
44. Macdougall IC, Walker R, Provenzano R, de Alvaro F, Locay HR, Nader PC, et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. CJASN. 2008;3:337–47.
45. Kessler M, Martínez-Castelao A, Siamopoulos KC, Villa G, Spinowitz B, Dougherty FC, et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. Hemodial Int. 2010;14:233–9.
46. Hoffmann-La Roche. A study of subcutaneous mircera in patients with chronic kidney disease, not on dialysis. 2011. http://clinicaltrials.gov/show/NCT00442702.
47. Locatelli F, Villa G, de Francisco ALM, Albertazzi A, Adrogue HJ, Dougherty FC, et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin. 2007;23:969–79.
48. Carrera F, Lok CE, de Francisco A, Locatelli F, Mann JFE, Canaud B, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Neph Dial Trans. 2010;25:4009–17.
49. Seliger SL, Zhang AD, Weir MR, Walker L, Hsu VD, Parsa A, et al. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kid Inter. 2011;80:288–94.
50. Mapes DL, Lopes AA, Satayathum S, McCullough KP, Goodkin DA, Locatelli F, et al. Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kid Inter. 2003;64:339–49.
51. Macdougall IC, Obrador GT. How important is transfusion avoidance in 2013? Neph Dial Trans. 2013;28:1092–9.
52. Choi J-Y, Yang CW, Kim Y-H, Joo KW, Yoo T-H, Lee KW, et al. Effect of conversion from ESA with shorter half-life to CERA once monthly for maintaining Hb concentration in pre-dialysis CKD patients. Kidney Blood Press Res. 2013;37:259–68.
53. O’Mara NB. Anemia in patients with chronic kidney disease. Diabetes Spectr. 2008;21:12–9.
54. Beyer-Westendorf J, Büller H. External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different? J Thromb Haemost. 2011;9:2153–8.
55. Taylor GJ, Wainwright P. Open label extension studies: research or marketing? BMJ. 2005;331:572–4.
56. Aggarwal HK, Jain D, Verma K. Efficacy and safety of continuous erythorpoietin receptor activator (C.E.R.A) in patients of chronic renal failure with anemia. Int. J Pharm Pharm Sci. 2011;3:292–7.